Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets

Probal Roy, Rebecca Torguson, Teruo Okabe, Tina L. Pinto Slottow, Daniel H. Steinberg, Kimberly Smith, Zhenyi Xue, Natalie Gevorkian, Lowell L. Satler, Kenneth M. Kent, William O. Suddath, Augusto D. Pichard, Ron Waksman*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    9 Citations (Scopus)


    Background: Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) both significantly reduce the need for repeat intervention compared to bare metal stents. Studies comparing the clinical outcomes of these stents in noncomplex subsets of patients and lesions demonstrate a similar safety and efficacy profile. The data for more complex subsets of patients and lesions remains conflicting. This study aimed to compare SES with PES in a selected population with a broad range of complex features. Methods and Results: The patient population consisted of 1,591 consecutive patients with complex features undergoing drug-eluting stent (DES) implantation. In the SES group there were 1,095 patients (1,653 lesions) and in the PES group 496 patients (802 lesions). In-hospital, 30-day, and 12-month clinical outcomes were compared between groups. No discernable difference in major adverse cardiac events (MACE) between SES and PES was detected at intermediate and longer-term follow-up (SES 22.4% vs. PES 20.5% at 12 months; P = 0.407). A trend toward increased angiographically documented stent thrombosis was observed in the SES group at both 3 and 12 months (SES 2.2% vs. PES 0.8% at 12 months; P = 0.051). When adopting the more inclusive definition of probable stent thrombosis, this trend was no longer seen. After adjusting for baseline differences between the two groups, there still remained no difference in MACE between SES and PES (HR 1.051 [CI 0.826-1.339] P = 0.685). The trend toward increased angiographically documented stent thrombosis in the SES group remained after adjustment for baseline differences (HR 2.836 [CI 0.968-8.311] P = 0.057). Conclusions: In a selected population with complex disease the rate of MACE was comparable between SES and PES, with higher overall rates of thrombosis and MACE compared to a noncomplex population. Thus, the focus should be directed to prevent late complications in this complex subset regardless of stent type selection.

    Original languageEnglish
    Pages (from-to)167-172
    Number of pages6
    JournalCatheterization and Cardiovascular Interventions
    Issue number2
    Publication statusPublished - 1 Aug 2007


    • Complex subsets
    • Paclitaxel-eluting stents
    • Sirolimus-eluting stents


    Dive into the research topics of 'Comparison between sirolimus- and paclitaxel-eluting stents in complex patient and lesions subsets'. Together they form a unique fingerprint.

    Cite this